| Nutriband is engaged in the development of a portfolio of transdermal pharmaceutical products. Co.'s key product is its abuse deterrent fentanyl transdermal system which it is developing to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches. Co. is developing a portfolio of transdermal pharmaceutical products to deliver commercially available drugs or biologics that are delivered by injection but with the potential to improve compliance and therapeutic outcomes. We show 4 historical shares outstanding datapoints in our coverage of NTRB's shares outstanding history.|
Understanding the changing numbers of NTRB shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NTRB versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NTRB by allowing them to research NTRB shares outstanding history
as well as any other stock in our coverage universe.